PubMedThe Cleft palate-craniofacial journal : official publication of the American Cleft Palate-Craniofacial Association2026-11-17
Safety of Recombinant Human Bone Morphogenetic Protein-2 Versus Iliac Crest Bone Graft in Alveolar Cleft Repair: Systematic Review and Meta-Analysis.
Alhamdan Abdulla A, Demetriou Efthimios E, Almeer Mohammad M, Demosthenous Christoforos C et al.
ObjectiveTo compare the safety and complication profiles of recombinant human bone morphogenetic protein (rhBMP-2) and iliac crest bone graft (ICBG) in alveolar cleft repair.DesignA systematic review and meta-analysis was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines and prospectively registered with PROSPERO (CRD420261340773).SettingPublished comparative studies identified through a comprehensive search of PubMed/MEDLINE, Embase and CENTRAL up to September 2026.Patients, Participants808 patients undergoing alveolar cleft repair, 395 with ICBG, 413 with rhBMP-2; across 7 studies (2 RCTs, 5 observational studies).InterventionsRhBMP-2 versus ICBG.Main Outcome MeasuresPrimary outcomes are graft failure, infection, oronasal fistula formation, postoperative swelling and wound dehiscence; secondary outcomes were operative time, length of stay and cost.ResultsSeven studies were included in the analysis. There were no statistically significant differences observed in graft failure (odds ratio [OR] = 0.86, 95% confidence interval [CI] 0.43-1.71, P = 0.67), wound dehiscence (OR = 1.33; 0.57-3.14) and fistula formation (OR = 0.46; 0.04-5.05). RhBMP-2 was associated with lower postoperative infection rates (OR = 0.20; 0.05-0.72; P = 0.01), although it was also associated with higher postoperative swelling (OR = 9.74, 95% CI 3.91-24.27, P < 0.00001). However, certainty of the evidence remained low.ConclusionsAlthough rhBMP-2 may be associated with lower infection rates, the increased postoperative swelling risk remains a concern. The limited number of studies, predominantly observational evidence, imprecision and heterogeneity limit the interpretation of these findings. Adequately powered RCTs are needed to establish the safety of rhBMP-2 relative to ICBG.